Biotech Values

[DewDiligence]

ACHN:

…the president states in his introductory remarks about ACH-1625 that ACHN has a "hold up in some clinical development here" among a few other initial remarks that are otherwise clearly positive... So, I'm not sure I understand the aforementioned statement as it was clearly out of context from the rest of the discussion regarding 1625. It was probably just a misstatement or I'm reading into it too much.

Nothing untoward—he simply meant that there’s work to do in the clinic before one can proclaim the program a success.